@entity5 and Its Association With the Development of Coronary Artery Calcification: An Assessment From the Multi-Ethnic Study of XXXX .

@entity1 @entity5 @entity460 @entity741 @entity731 @entity65
BACKGROUND: Although @entity5 and its corresponding therapies are associated with @entity741 , the temporal relationship between @entity5 and the development of coronary artery @entity460 (CAC), a marker of subclinical @entity731 , is unknown. METHODS AND RESULTS: Among 3122 @entity1 and @entity1 free of @entity65 and @entity5 in the Multi-Ethnic Study of @entity731 trial, CAC scoring was performed at baseline (2000-2002) and at follow-up (2010-2012). Over this 10-year period, 85 @entity1 (age 63.6  8.3 years) and 50 @entity1 (age 62.1  9.8 years) were diagnosed with @entity5 (predominantly breast, lung, or uterine [52%] in @entity1 and prostate or colorectal [78%] in @entity1 ). The other 2987 subjects (age 59.6  9.2 years for @entity1 , 59.7  9.4 years for @entity1 ) remained @entity5 free. The incidence of new CAC (baseline Agatston score of zero converting to detectable CAC) was modeled with relative risk regression and compared for @entity5 versus no @entity5 . Increase in pre-existing CAC was compared in these groups using linear regression of log transformed CAC. The incidence of CAC was independently associated with @entity5 history (relative risk 1.32 [P=0.04] and 1.29 [P=0.01] for @entity1 and @entity1 , respectively). In @entity1 with CAC at baseline, a clear difference of CAC progression was not observed between @entity5 and noncancer @entity1 (P=0.6 for @entity1 , P=0.2 for @entity1 ). CONCLUSIONS: A diagnosis of @entity5 is associated with the development of CAC even after accounting for @entity731 risk factors. However, in individuals with pre-existing CAC, it is not clear whether the presence of @entity5 accelerates CAC over time.
